Growth hormone therapy for protein catabolism

Area of Science:

• Endocrinology
• Metabolic Research
• Clinical Nutrition

Background:

• Growth hormone (GH) and insulin-like growth factor I (IGF-I) demonstrate consistent efficacy in various catabolic conditions.
• Short-term administration of GH and IGF-I can enhance protein synthesis and preserve lean body mass.

Purpose of the Study:

• To review the metabolic and clinical effects of GH and IGF-I in catabolic states.
• To explore the potential benefits and adverse effects of GH and IGF-I therapy, including combination therapy.

Main Methods:

• Review of existing studies on GH and IGF-I in catabolic conditions.
• Analysis of metabolic and clinical endpoints, including protein synthesis, lean body mass, hospital stay, mortality, and organ function.
• Discussion of adverse effects, glycaemic control, and the potential of co-administration.

Main Results:

• GH and IGF-I improve net protein synthesis and preserve lean body mass.
• Clinical benefits include reduced hospital stay, improved respiratory and muscle function, and enhanced organ function.
• Adverse effects are uncommon, mainly related to glycaemic control, with differential effects on insulin concentrations.

Conclusions:

• GH and IGF-I show significant anabolic effects in catabolic conditions.
• Co-administration of GH and IGF-I may offer synergistic benefits by enhancing anabolic actions and balancing glycaemic control.
• Further large-scale clinical trials are needed to confirm these findings and assess cost-effectiveness.